Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,184,025
  • Shares Outstanding, K 103,648
  • Annual Sales, $ 494,370 K
  • Annual Income, $ 19,810 K
  • 60-Month Beta 1.10
  • Price/Sales 27.47
  • Price/Cash Flow 437.77
  • Price/Book 36.15
Trade NVCR with:

Options Overview Details

View History
  • Implied Volatility 64.98%
  • Historical Volatility 31.69%
  • IV Percentile 79%
  • IV Rank 58.41%
  • IV High 82.73% on 02/24/21
  • IV Low 40.06% on 05/27/21
  • Put/Call Vol Ratio 0.09
  • Today's Volume 290
  • Volume Avg (30-Day) 785
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 4,318
  • Open Int (30-Day) 7,829

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.05
  • Number of Estimates 6
  • High Estimate 0.00
  • Low Estimate -0.10
  • Prior Year 0.09
  • Growth Rate Est. (year over year) -155.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
123.20 +4.19%
on 09/16/21
143.69 -10.67%
on 09/09/21
-4.07 (-3.07%)
since 08/20/21
3-Month
123.20 +4.19%
on 09/16/21
232.76 -44.85%
on 06/24/21
-92.16 (-41.79%)
since 06/21/21
52-Week
100.13 +28.19%
on 09/22/20
232.76 -44.85%
on 06/24/21
+23.25 (+22.12%)
since 09/21/20

Most Recent Stories

More News
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with Roche (SIX: RO. ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roche's...

NVCR : 128.36 (+0.91%)
FDA Grants Breakthrough Device Designation to the NovoTTF-200T(TM) System for Advanced Liver Cancer

Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has granted breakthrough designation to the NovoTTF-200T System, a Tumor Treating Fields (TTFields) delivery...

NVCR : 128.36 (+0.91%)
NovoCure (NVCR) Reports Q2 Loss, Misses Revenue Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of -800.00% and -5.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 128.36 (+0.91%)
Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update

--Invested record $50 million in research and development initiatives across brain, thoracic and abdominal programs

NVCR : 128.36 (+0.91%)
4 Overvalued Healthcare Stocks to Avoid

Despite unprecedented advancements in the healthcare industry, investors are currently shifting their focus toward outdoor stocks to benefit from the fast-paced economic reopening. In-part because of this...

NVCR : 128.36 (+0.91%)
TXG : 160.99 (-0.50%)
GDRX : 46.36 (+0.67%)
DOCS : 87.05 (+1.62%)
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and the...

NVCR : 128.36 (+0.91%)
NVE Schedules Conference Call on First-Quarter Results

NVE Corporation (Nasdaq: NVEC) announced that it plans to release its financial results for the quarter ended June 30, 2021 on Wednesday, July 21, 2021 after the close of the Nasdaq Regular Market. The...

NVCR : 128.36 (+0.91%)
NVEC : 64.26 (-0.79%)
Novocure to Report Second Quarter 2021 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2021 on Thursday, July 29, 2021, before the U.S. financial markets open. Novocure's management will...

NVCR : 128.36 (+0.91%)
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on

Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.

NVS : 83.05 (+0.30%)
PKI : 184.80 (+0.47%)
OCX : 3.87 (+0.52%)
CTLT : 136.09 (+0.08%)
NVCR : 128.36 (+0.91%)
CRDF : 6.70 (+1.52%)
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer

--In patients who completed at least 12 weeks of Tumor Treating Fields treatment, disease control rate was 91% with 18% objective response

NVCR : 128.36 (+0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 132.87
2nd Resistance Point 131.26
1st Resistance Point 129.81
Last Price 128.36
1st Support Level 126.75
2nd Support Level 125.14
3rd Support Level 123.69

See More

52-Week High 232.76
Fibonacci 61.8% 182.10
Fibonacci 50% 166.45
Fibonacci 38.2% 150.79
Last Price 128.36
52-Week Low 100.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar